Group 1 - The core viewpoint of the article is that Zai Jian Pharmaceutical (688266.SH) reported a significant increase in revenue for the first half of 2025, but still faced a net loss [1] - The company's total revenue reached 376 million yuan, an increase of 135 million yuan compared to the same period last year, marking a 56.07% year-on-year growth [1] - The net profit attributable to shareholders was -72.8 million yuan, indicating ongoing financial challenges despite revenue growth [1] Group 2 - The latest debt-to-asset ratio of the company is 60.77% [3] - The gross profit margin improved to 89.67%, up by 1.28 percentage points from the previous quarter [3] - The return on equity (ROE) stands at -6.19%, reflecting negative profitability [3] Group 3 - The diluted earnings per share (EPS) is -0.28 yuan [3] - The total asset turnover ratio increased to 0.13 times, a 55.60% rise compared to the same period last year [3] - The inventory turnover ratio improved to 0.22 times, up by 61.05% year-on-year [3] Group 4 - The number of shareholders is 8,795, with the top ten shareholders holding 121 million shares, accounting for 45.74% of the total share capital [3] - The largest shareholder, Zelin Sheng, holds 18.85% of the shares [3] - Other significant shareholders include Ningbo Zeao Venture Capital and Lu Huiping, holding 6.23% and 4.77% respectively [3]